Latest Deals
Upon completion, Exact Sciences will operate as Abbott’s subsidiary. Credit: Michael Vi/Shutterstock.com
Abbott to acquire all outstanding shares in Exact Sciences
Abbott has signed a definitive agreement to acquire all of Exact Sciences’ outstanding shares for an enterprise value of $23bn, marking its entry into cancer diagnostics. Abbott will pay $105 per share in cash, valuing the equity at about $21bn, and will assume around $1.8bn in net debt. Once completed, Exact Sciences will operate as an Abbott subsidiary, and Abbott’s annual diagnostics sales are expected to exceed $12bn.
GE HealthCare to buy imaging software provider Intelerad
GE HealthCare has announced an agreement to acquire medical imaging software provider Intelerad for a cash consideration of $2.3bn (C$3.24bn). This move is intended to support GE HealthCare’s objective to significantly increase its range of cloud-enabled products by 2028. Founded in 1999 in Canada, Intelerad offers products intended for cardiology and radiology. Its cloud-first solutions are used in both outpatient and inpatient healthcare environments.
Solventum bolsters wound care portfolio with $850m Acera Surgical deal
Solventum has acquired US-based Acera Surgical in a deal worth up to $850m, positioning the company to progress in the synthetic tissue matrices technology space. Solventum, which span out from 3M in 2024, will pay $725m in cash up front to acquire Acera, with up to $125m in cash payments predicated on hitting certain future milestones.
Distalmotion secures $150m to expand US robotic surgery system
Distalmotion has closed a Series G funding round totalling $150m to expedite the expansion of its soft tissue robotic surgery system, DEXTER, in the US. The funds will also be directed to support product and clinical development efforts that are currently underway. The round was spearheaded by Revival Healthcare Capital, with participation from inside investors.
